Aktuellt
SENASTE
Redeye updates its view on Acarix following its Q2 2024 report. While revenues increase both y/y and q/q the ramp-up is taking longer than we were hoping for. On the other hand, progress is being made on several fronts, and the potential in the business case remains high. We trim our base case.
LÄS MER
